Glofitamab (Genetical Recombination)



Glofitamab is a recombinant trivalent bispecific monoclonal antibody against CD20 and CD3ε chain, in which amino acid residues of anti-CD20/CD3ε H-chain at positions 1 – 119, 120 – 217, 218 – 223, 224 – 233, 234 – 342, 343 – 344 and 345 – 674 correspond to VH, CH1, a part of hinge of anti-CD20 H-chain, linker, VL of anti-CD3ε L-chain, linker and constant regions of anti-CD3ε H-chain, respectively, and amino acid residues of anti-CD3ε L-chain at positions of 1 – 125 and 126 – 232 correspond to VH of anti-CD3ε H-chain and CL of anti-CD3ε L-chain, respectively. The complementarity-determining regions of each chain are derived from mouse antibodies and other regions are derived from human IgG1. In the anti-CD20 H-chain, the amino acid residues are substituted at 9 positions (K149E, K215E, L236A, L237A, P331G, Y351C, T368S, L370A, Y409V), and in the anti-CD20 L-chain, the amino acid residues are substituted at 2 positions (E128R, Q129K), and in the anti-CD20/CD3ε H-chain, the amino acid residues are substituted at 7 positions (K149E, K215E, L461A, L462A, P556G, S581C, T593W). Glofitamab is produced in CHO cells. Glofitamab is a glycoprotein (molecular weight: ca. 197,000) composed of an anti-CD20 H-chain (γ1-chain) consisting of 449 amino acid residues, two anti-CD20 L-chains (κ-chains) consisting of 219 amino acid residues each, an anti-CD20/CD3ε H-chain (γ1-chain) consisting of 674 amino acid residues, and an anti-CD3ε L-chain consisting of 232 amino acid residues, in which anti-CD3ε variable region of anti-CD20/CD3ε H-chain and constant region of anti-CD3ε L-chain are derived from λ-chain and κ-chain, respectively.

[2229047-91-8]